CANSoR

We are building the technology that can change the way we screen Aggressive Cancers. Although, there is an existing blood test (PSA) for prostate cancer; misdiagnosis and over-treatment are commonplace due to this test’s inaccuracy. Therefore, there is a need to develop a better, more accurate screening method for prostate cancer That’s why Cansor is developing a point-of-care test with high sensitivity and specificity using cell-free DNA and state-of-art AI technology. We believe our method can revolutionise the way we detect prostate cancer and other cancer types by improving diagnosis, decreasing healthcare cost and reducing invasive/painful screening methods.

Website

https://cansor.co.uk

External link for CANSoR

Industry

Biotechnology Research

Company size

2-10 employees

Headquarters

London, England

Type

Privately Held

Founded

2021